Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Active Biotech (STO:ACTI) Lund, Sweden, 17 September 2008 - Active Biotech (OMX Nordic: ACTI) is scheduled to present at the UBS Global Life Sciences Conference on Tuesday, September 23 at the Grand Hyatt Hotel in New York City, US. During the presentation, an update regarding Active Biotech's development programs will be provided.
The presentation will include the Phase III projects laquinimod, a novel oral immunomodulatory drug for the treatment of Multiple Sclerosis, which is licensed to Teva Pharmaceutical Industries Ltd and ANYARA, Active Biotech's novel concept for tumor therapy in a Phase III study for renal cell cancer. Also, retrospective Phase I bone scan evaluation data from the prostate cancer project TASQ will be presented. An update will also be given on the SLE project 57-57 and the new project around the mode of action of the quinoline technology.
The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site.
To access the live and replay presentations please go to - www.activebiotech.com.
The presentation will take place on September 23, at 1:00 pm US Eastern Time / 19:00 Central European Time.
About Active Biotech Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. Please visit www.activebiotech.com for more information.
Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 11:00 a.m. CET on September 17, 2008.
Contacts:
Active Biotech AB Göran Forsberg, VP Communication & Business Development P.O. Box 724, SE-220 07 Lund, Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00
